Brusatol may serve as potential adjuvant therapy for pancreatic ductal adenocarcinoma

Less than a year in­to a rocky roll­out for its gene ther­a­py Roc­ta­vian, Bio­Marin is now talk­ing about whether the prod­uct might be a bet­ter

Flag­ship Pi­o­neer­ing, the 25-year-old life sci­ences in­cu­ba­tor and in­vestor, has reeled in $3.6 bil­lion to build an­oth­er 25 or so com­pa­nies, it Sign up to